Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study - Archive ouverte HAL Access content directly
Journal Articles Lancet Oncology Year : 2016

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study

Mahmoud Fekih
  • Function : Author
Emmanuelle Charafe-Jauffret
François-Clément Bidard
Patrice Viens
  • Function : Author
Jérôme Lemonnier
  • Function : Author
Jean-Yves Pierga
  • Function : Author
Not file

Dates and versions

hal-03623735 , version 1 (29-03-2022)

Identifiers

Cite

François Bertucci, Mahmoud Fekih, Aurélie Autret, Thierry Petit, Florence Dalenc, et al.. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. Lancet Oncology, 2016, 17 (5), pp.600-611. ⟨10.1016/s1470-2045(16)00011-5⟩. ⟨hal-03623735⟩
19 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More